Evogene Ltd
Evogene is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost.
Nasdaq: EVGN
IR Website: https://www.evogene.com/investor-relations/
Headquarters: Rehovot, Israel
Content provided by Evogene on 2-10-22.
TALK TO MANAGEMENT
The Evogene management team is always available to talk to current and potential investors. They're happy to answer any questions you may have and tell you what makes their story unique. Please fill out this form, and we will connect you shortly.
Summary
Evogene is a computational biology company aiming to revolutionize the development of life-science based products by utilizing cutting edge technologies to increase probability of success while reducing development time and cost.
We established three unique technological engines, MicroBoost AI, ChemPass AI and GeneRator AI, leveraging Big Data and Artificial Intelligence and incorporating deep multidisciplinary understanding in life sciences.
Each technological engine is focused on the discovery and development of products based on one of the following core components: microbes (Microboost AI), small molecules (ChemPass AI), and genetic elements (GeneRator AI).
The company uses its technological engines to develop products through subsidiaries and with strategic partners. Currently, our main subsidiaries utilize the technological engines to develop novel products as follows: human microbiome-based therapeutics by Biomica Ltd., medical cannabis by Canonic Ltd., ag-chemicals by AgPlenus and ag-biologicals by Lavie Bio Ltd.
Investor Presentation
Recent News
Evogene to Attend the 34th Annual ROTH Investor Conference in Dana Point California Between March 13-15, 2022
Mar 3, 2022
Canonic Announces Professor Itamar Grotto Joining its Board of Directors
Feb 16, 2022
Evogene Financial Results and Earnings Announcement Schedule for the Full Year and Fourth Quarter of 2021
Feb 15, 2022
Evogene to Present at Aegis Virtual Conference
Feb 7, 2022
Canonic Announces Shipment of its Cannabis Varieties to Europe
Jan 31, 2022
Evogene to Participate in Edison Group’s Global Healthcare “Open House” Virtual Conference from January 25-27th, 2022
Jan 19, 2022
Canonic Announces Positive Results in Pre-Clinical Studies in its Precise Product Program for Medical Cannabis
Jan 18, 2022
Biomica Announces Clearance for First-in-Human Phase I Study of BMC-128 in Combination with Bristol Myers Squibb’s Anti-PD-1 Opdivo®
Jan 11, 2022
Management Overview
Ofer Haviv
President and Chief Executive Officer
Mr. Ofer Haviv holds the position of Evogene’s President and CEO as of late 2004. Prior to that he held the positions of company COO and CFO from 2002 to 2004 and was involved in Evogene’s spin-off from Compugen in 2002. At Compugen, he held the position of Director of Finance and Treasurer of Compugen (NASDAQ: CGEN) for four years, during which time the company completed two private placements and an IPO on NASDAQ
Mr. Haviv holds a B.A. degree in Economics and Accounting from Faculty of Management, Tel Aviv University and is a Certified Public Accountant in Israel.
Dr. Nir Arbel
Chief Product Officer
Dr. Nir Arbel was appointed as Chief Product Officer in August, 2021. Dr. Arbel has over ten years of experience in Biotech and MedTech companies in product development and commercialization. Prior to joining Evogene, Dr. Arbel served as CEO and Co-Founder of Carmentix Pte Ltd, Singapore, a company focused on high risk pregnancy prognosis. Prior to that, Dr. Arbel served as the Operating Partner in Esco Ventures, a MedTech fund based in Singapore.
Dr. Arbel holds a Ph.D. in Biochemistry from Ben Gurion University.
Liat Foigel Wejgman
Vice President, Human Resources
Ms. Liat Foigel Wejgman was appointed Vice President Human Resources in January 2022, previously serving as Director of Human Resources from 2018. Ms. Foigel Wejgman joined Evogene in 2015 and has held various positions in the company over the years. Prior to joining Evogene Ms. Foigel Wejgman worked in human resource positions at an online trading leading company.
Ms. Foigel Wejgman holds a B.A. degree in Social Science with a major in Technological Marketing from Sapir College.
Mark Kapel
Chief Technology Officer
Mr. Kapel was appointed as Chief Technology Officer in 2018, previously serving as Director of Information Technologies & Data Management from 2013. Mr. Kapel joined Evogene in 2005 and has held various positions in the company over the years.
Mr. Kapel holds a B.Sc. in Physics & Computers from the Ben Gurion University of Negev, an MBA majoring in Management of Technology from Tel Aviv University’s Faculty of Management – Recanati Graduate School of Business Administration.
Dorit Kreiner
Chief Financial Officer
Ms. Dorit Kreiner was appointed as CFO in February 2019, bringing over 20 years of senior financial management experience in both public and private companies. Most recently, Ms. Kreiner served as Chief Financial Officer of Therapix (TASE: THXBY) and NRGene. Previously, Ms. Kreiner served as Director of Finance of Evogene from June 2004 through August 2011.
Ms. Kreiner holds a BA in Accounting and Economics from Tel Aviv University and she is a Certified Public Accountant in Israel. Additionally, Ms. Kreiner holds an MBA in Finance and Marketing from Tel Aviv University and a Bachelor of Law from the College of Management.
Sassi Masliah
Executive Vice President, Corporate Development
Mr. Sassi Masliah was appointed as Executive Vice President Corporate Development in February 2022. Mr. Masliah has held various positions within Evogene since 2011, most recently as Evogene’s Vice President for Legal Affairs and Corporate Secretary.
Mr. Masliah holds an LL.B. and B.A. in economics from the Tel-Aviv University.
Risks & Disclosures
This communication is neither an offer to sell nor a solicitation of an offer to buy, nor a recommendation of any securities of the company mentioned herein.
Evogene Ltd (the “Company”) and its counsel have reviewed the content of this page as well as the accompanying presentation (“Company Presentation”) displayed on this page. To the best of its knowledge, the Company does not believe this content to be misleading or inaccurate in any material respect, nor does it believe there are any material omissions with respect to such content. The Company does not believe the contents of the page or the Company Presentation to contain any non-public material information.
Information and opinions presented in the Company Presentation are provided by the Company, and b2i digital makes no representation as to their accuracy or completeness. The information contained on this page is not intended to constitute any form of advice, and the information provided is not intended to provide a sufficient basis on which to make an investment decision. It is not investment research, nor does it constitute a research recommendation, as it does not constitute substantive research or analysis. This information is not to be relied upon in substitution for the exercise of independent judgment.
Information, opinions and estimates contained on this page or in the Company Presentation reflect judgments by the Company as of the original date of publication by the Company and are subject to change without notice. Past performance should not be taken as an indication or guarantee of future performance, and no representation or warranty, express or implied is made regarding future performance.
A complete description of the risks and uncertainties relating to the Company and its securities can be found in the company's filings with the U.S. Securities and Exchange Commission available for free at www.sec.gov.
Information on this page may relate to penny stocks, which may also be referred to as low-priced stocks. Penny stocks are low-priced shares typically issued by small companies. Penny stocks involve greater than normal risk, they may be less liquid than other stocks (i.e., more difficult to sell), and there may be less reliable information available regarding such stocks. Investors in penny stocks should be prepared for the possibility that they may lose their entire investment.
B2I DIGITAL, Inc. is a marketing sponsor of the Roth 34th Annual Roth Conference. B2I DIGITAL, Inc. is not an affiliate of Roth Capital Partners, LLC (“Roth”) and is not authorized to represent or act on behalf of Roth ,in any capacity. Roth has not reviewed and approved the content contained on the b2idigital.com website.
